APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiangiogenic Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antiangiogenic Drugs Industry Growth and Trends Forecast to 2032

27 December 2025107 pages

Choose your research edition.

Industry ResearchAntiangiogenic Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiangiogenic Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Antiangiogenic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiangiogenic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiangiogenic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antiangiogenic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiangiogenic Drugs include Chia Tai Tianqing, Sanofi, Jiangsu Hengrui Pharmaceuticals, Simcere, Roche, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antiangiogenic Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antiangiogenic Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antiangiogenic Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antiangiogenic Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antiangiogenic Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antiangiogenic Drugs Market by Company

Chia Tai Tianqing

Sanofi

Jiangsu Hengrui Pharmaceuticals

Simcere

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Antiangiogenic Drugs Segment by Type

Macromolecular Single-target Angiogenesis Inhibitor

Endogenous Pan-target Angiogenesis Inhibitor

Small Molecule Multi-target Angiogenesis Inhibitor

Antiangiogenic Drugs Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Antiangiogenic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiangiogenic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiangiogenic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiangiogenic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiangiogenic Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antiangiogenic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Macromolecular Single-target Angiogenesis Inhibitor Table 2. Major Company of Endogenous Pan-target Angiogenesis Inhibitor Table 3. Major Company of Small Molecule Multi-target Angiogenesis Inhibitor Table 4. Global Antiangiogenic Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 6. Global Antiangiogenic Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Antiangiogenic Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Antiangiogenic Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 11. Global Antiangiogenic Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Antiangiogenic Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Antiangiogenic Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Antiangiogenic Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 16. North America Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 18. Europe Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 22. Latin America Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Antiangiogenic Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Antiangiogenic Drugs Industry Trends Table 26. Antiangiogenic Drugs Industry Drivers Table 27. Antiangiogenic Drugs Industry Opportunities and Challenges Table 28. Antiangiogenic Drugs Industry Restraints Table 29. Global Antiangiogenic Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Antiangiogenic Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Antiangiogenic Drugs Sales by Company (2021-2026) & (K Units) Table 32. Global Antiangiogenic Drugs Sales Share by Company (2021-2026) Table 33. Global Antiangiogenic Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Antiangiogenic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Antiangiogenic Drugs Major Company Production Sites and Headquarters Table 36. Global Antiangiogenic Drugs Company, Product Type & Application Table 37. Global Antiangiogenic Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Antiangiogenic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Antiangiogenic Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Antiangiogenic Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global Antiangiogenic Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Antiangiogenic Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Antiangiogenic Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Antiangiogenic Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Antiangiogenic Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Antiangiogenic Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Antiangiogenic Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Antiangiogenic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Antiangiogenic Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global Antiangiogenic Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Antiangiogenic Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Antiangiogenic Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Antiangiogenic Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Antiangiogenic Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Antiangiogenic Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Antiangiogenic Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 63. North America Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 65. Europe Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 69. Latin America Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Antiangiogenic Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Chia Tai Tianqing Company Information Table 73. Chia Tai Tianqing Business Overview Table 74. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio Table 76. Chia Tai Tianqing Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sanofi Antiangiogenic Drugs Product Portfolio Table 81. Sanofi Recent Development Table 82. Jiangsu Hengrui Pharmaceuticals Company Information Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview Table 84. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development Table 87. Simcere Company Information Table 88. Simcere Business Overview Table 89. Simcere Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Simcere Antiangiogenic Drugs Product Portfolio Table 91. Simcere Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Roche Antiangiogenic Drugs Product Portfolio Table 96. Roche Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Pfizer Antiangiogenic Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. Novartis Company Information Table 103. Novartis Business Overview Table 104. Novartis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis Antiangiogenic Drugs Product Portfolio Table 106. Novartis Recent Development Table 107. Janssen Biotech Company Information Table 108. Janssen Biotech Business Overview Table 109. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Janssen Biotech Antiangiogenic Drugs Product Portfolio Table 111. Janssen Biotech Recent Development Table 112. Exelixis Company Information Table 113. Exelixis Business Overview Table 114. Exelixis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Exelixis Antiangiogenic Drugs Product Portfolio Table 116. Exelixis Recent Development Table 117. Eli Lilly Company Information Table 118. Eli Lilly Business Overview Table 119. Eli Lilly Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Eli Lilly Antiangiogenic Drugs Product Portfolio Table 121. Eli Lilly Recent Development Table 122. Eisai Company Information Table 123. Eisai Business Overview Table 124. Eisai Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Eisai Antiangiogenic Drugs Product Portfolio Table 126. Eisai Recent Development Table 127. Boehringer Ingelheim Company Information Table 128. Boehringer Ingelheim Business Overview Table 129. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio Table 131. Boehringer Ingelheim Recent Development Table 132. Bayer Company Information Table 133. Bayer Business Overview Table 134. Bayer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Bayer Antiangiogenic Drugs Product Portfolio Table 136. Bayer Recent Development Table 137. AstraZeneca Company Information Table 138. AstraZeneca Business Overview Table 139. AstraZeneca Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. AstraZeneca Antiangiogenic Drugs Product Portfolio Table 141. AstraZeneca Recent Development Table 142. North America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. North America Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 144. North America Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 145. North America Antiangiogenic Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 146. North America Antiangiogenic Drugs Sales Market Share Forecast by Country (2027-2032) Table 147. North America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. North America Antiangiogenic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 149. North America Antiangiogenic Drugs Market Share by Country (2021-2026) Table 150. North America Antiangiogenic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. North America Antiangiogenic Drugs Market Share Forecast by Country (2027-2032) Table 152. Europe Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. Europe Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 154. Europe Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 155. Europe Antiangiogenic Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 156. Europe Antiangiogenic Drugs Sales Market Share Forecast by Country (2027-2032) Table 157. Europe Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Europe Antiangiogenic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 159. Europe Antiangiogenic Drugs Market Share by Country (2021-2026) Table 160. Europe Antiangiogenic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Europe Antiangiogenic Drugs Market Share Forecast by Country (2027-2032) Table 162. Asia-Pacific Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Asia-Pacific Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 164. Asia-Pacific Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 165. Asia-Pacific Antiangiogenic Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 166. Asia-Pacific Antiangiogenic Drugs Sales Market Share Forecast by Country (2027-2032) Table 167. Asia-Pacific Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Asia-Pacific Antiangiogenic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 169. Asia-Pacific Antiangiogenic Drugs Market Share by Country (2021-2026) Table 170. Asia-Pacific Antiangiogenic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Asia-Pacific Antiangiogenic Drugs Market Share Forecast by Country (2027-2032) Table 172. Latin America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 173. Latin America Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 174. Latin America Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 175. Latin America Antiangiogenic Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 176. Latin America Antiangiogenic Drugs Sales Market Share Forecast by Country (2027-2032) Table 177. Latin America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Latin America Antiangiogenic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 179. Latin America Antiangiogenic Drugs Market Share by Country (2021-2026) Table 180. Latin America Antiangiogenic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Latin America Antiangiogenic Drugs Market Share Forecast by Country (2027-2032) Table 182. Middle East and Africa Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 183. Middle East and Africa Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 184. Middle East and Africa Antiangiogenic Drugs Sales Market Share by Country (2021-2026) Table 185. Middle East and Africa Antiangiogenic Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 186. Middle East and Africa Antiangiogenic Drugs Sales Market Share Forecast by Country (2027-2032) Table 187. Middle East and Africa Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Middle East and Africa Antiangiogenic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 189. Middle East and Africa Antiangiogenic Drugs Market Share by Country (2021-2026) Table 190. Middle East and Africa Antiangiogenic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Middle East and Africa Antiangiogenic Drugs Market Share Forecast by Country (2027-2032) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Antiangiogenic Drugs Distributors List Table 195. Antiangiogenic Drugs Customers List Table 196. Research Programs/Design for This Report Table 197. Authors List of This Report Table 198. Secondary Sources Table 199. Primary Sources List of Figures Figure 1. Antiangiogenic Drugs Image Figure 2. Global Antiangiogenic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiangiogenic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiangiogenic Drugs Sales (2021-2032) & (K Units) Figure 5. Macromolecular Single-target Angiogenesis Inhibitor Image Figure 6. Global Macromolecular Single-target Angiogenesis Inhibitor Sales YoY Growth (2021-2032) & (K Units) Figure 7. Endogenous Pan-target Angiogenesis Inhibitor Image Figure 8. Global Endogenous Pan-target Angiogenesis Inhibitor Sales YoY Growth (2021-2032) & (K Units) Figure 9. Small Molecule Multi-target Angiogenesis Inhibitor Image Figure 10. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Antiangiogenic Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Antiangiogenic Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Antiangiogenic Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Antiangiogenic Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Antiangiogenic Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Antiangiogenic Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Antiangiogenic Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Antiangiogenic Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Antiangiogenic Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Antiangiogenic Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Antiangiogenic Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Antiangiogenic Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Antiangiogenic Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Cancer Therapy Image Figure 26. Global Cancer Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Inflammatory and Autoimmune Diseases Image Figure 28. Global Inflammatory and Autoimmune Diseases Sales YoY Growth (2021-2032) & (K Units) Figure 29. Ophthalmic Diseases Image Figure 30. Global Ophthalmic Diseases Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Antiangiogenic Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Antiangiogenic Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Antiangiogenic Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Antiangiogenic Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Antiangiogenic Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Antiangiogenic Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Antiangiogenic Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Antiangiogenic Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Antiangiogenic Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Antiangiogenic Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Antiangiogenic Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Antiangiogenic Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Antiangiogenic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Antiangiogenic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Antiangiogenic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Antiangiogenic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Antiangiogenic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Antiangiogenic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Antiangiogenic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Antiangiogenic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Antiangiogenic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Antiangiogenic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Antiangiogenic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antiangiogenic Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Antiangiogenic Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Macromolecular Single-target Angiogenesis Inhibitor
  • Endogenous Pan-target Angiogenesis Inhibitor
  • Small Molecule Multi-target Angiogenesis Inhibitor
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Simcere
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiangiogenic Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antiangiogenic Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antiangiogenic Drugs Market by Type
  6. 1.3.1 Macromolecular Single-target Angiogenesis Inhibitor
  7. 1.3.2 Endogenous Pan-target Angiogenesis Inhibitor
  8. 1.3.3 Small Molecule Multi-target Angiogenesis Inhibitor
  9. 1.4 Global Antiangiogenic Drugs Market Size by Type
  10. 1.4.1 Global Antiangiogenic Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Antiangiogenic Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Antiangiogenic Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Antiangiogenic Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Antiangiogenic Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Antiangiogenic Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Antiangiogenic Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Antiangiogenic Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antiangiogenic Drugs Industry Trends
  2. 2.2 Antiangiogenic Drugs Industry Drivers
  3. 2.3 Antiangiogenic Drugs Industry Opportunities and Challenges
  4. 2.4 Antiangiogenic Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antiangiogenic Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Antiangiogenic Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Antiangiogenic Drugs Price (2021-2026)
  4. 3.4 Global Antiangiogenic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiangiogenic Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Antiangiogenic Drugs Company, Product Type & Application
  7. 3.7 Global Antiangiogenic Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiangiogenic Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiangiogenic Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiangiogenic Drugs Tier 1, Tier 2, and Tier 3
4 Antiangiogenic Drugs Regional Status and Outlook
  1. 4.1 Global Antiangiogenic Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antiangiogenic Drugs Historic Market Size by Region
  3. 4.2.1 Global Antiangiogenic Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antiangiogenic Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antiangiogenic Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antiangiogenic Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Antiangiogenic Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antiangiogenic Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antiangiogenic Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antiangiogenic Drugs by Application
  1. 5.1 Antiangiogenic Drugs Market by Application
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Antiangiogenic Drugs Market Size by Application
  7. 5.2.1 Global Antiangiogenic Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Antiangiogenic Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Antiangiogenic Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Antiangiogenic Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Antiangiogenic Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Antiangiogenic Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Antiangiogenic Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Antiangiogenic Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai Tianqing
  2. 6.1.1 Chia Tai Tianqing Company Information
  3. 6.1.2 Chia Tai Tianqing Business Overview
  4. 6.1.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
  6. 6.1.5 Chia Tai Tianqing Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Jiangsu Hengrui Pharmaceuticals
  14. 6.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 6.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 6.3.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
  18. 6.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 6.4 Simcere
  20. 6.4.1 Simcere Company Information
  21. 6.4.2 Simcere Business Overview
  22. 6.4.3 Simcere Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Simcere Antiangiogenic Drugs Product Portfolio
  24. 6.4.5 Simcere Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Roche Antiangiogenic Drugs Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Antiangiogenic Drugs Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novartis Antiangiogenic Drugs Product Portfolio
  42. 6.7.5 Novartis Recent Developments
  43. 6.8 Janssen Biotech
  44. 6.8.1 Janssen Biotech Company Information
  45. 6.8.2 Janssen Biotech Business Overview
  46. 6.8.3 Janssen Biotech Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
  48. 6.8.5 Janssen Biotech Recent Developments
  49. 6.9 Exelixis
  50. 6.9.1 Exelixis Company Information
  51. 6.9.2 Exelixis Business Overview
  52. 6.9.3 Exelixis Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Exelixis Antiangiogenic Drugs Product Portfolio
  54. 6.9.5 Exelixis Recent Developments
  55. 6.10 Eli Lilly
  56. 6.10.1 Eli Lilly Company Information
  57. 6.10.2 Eli Lilly Business Overview
  58. 6.10.3 Eli Lilly Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
  60. 6.10.5 Eli Lilly Recent Developments
  61. 6.11 Eisai
  62. 6.11.1 Eisai Company Information
  63. 6.11.2 Eisai Business Overview
  64. 6.11.3 Eisai Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Eisai Antiangiogenic Drugs Product Portfolio
  66. 6.11.5 Eisai Recent Developments
  67. 6.12 Boehringer Ingelheim
  68. 6.12.1 Boehringer Ingelheim Company Information
  69. 6.12.2 Boehringer Ingelheim Business Overview
  70. 6.12.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
  72. 6.12.5 Boehringer Ingelheim Recent Developments
  73. 6.13 Bayer
  74. 6.13.1 Bayer Company Information
  75. 6.13.2 Bayer Business Overview
  76. 6.13.3 Bayer Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Bayer Antiangiogenic Drugs Product Portfolio
  78. 6.13.5 Bayer Recent Developments
  79. 6.14 AstraZeneca
  80. 6.14.1 AstraZeneca Company Information
  81. 6.14.2 AstraZeneca Business Overview
  82. 6.14.3 AstraZeneca Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
  84. 6.14.5 AstraZeneca Recent Developments
7 North America by Country
  1. 7.1 North America Antiangiogenic Drugs Sales by Country
  2. 7.1.1 North America Antiangiogenic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antiangiogenic Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Antiangiogenic Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antiangiogenic Drugs Market Size by Country
  6. 7.2.1 North America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antiangiogenic Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Antiangiogenic Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antiangiogenic Drugs Sales by Country
  2. 8.1.1 Europe Antiangiogenic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antiangiogenic Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Antiangiogenic Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antiangiogenic Drugs Market Size by Country
  6. 8.2.1 Europe Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antiangiogenic Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antiangiogenic Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antiangiogenic Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Antiangiogenic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antiangiogenic Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antiangiogenic Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antiangiogenic Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antiangiogenic Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antiangiogenic Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antiangiogenic Drugs Sales by Country
  2. 10.1.1 South America Antiangiogenic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antiangiogenic Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Antiangiogenic Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antiangiogenic Drugs Market Size by Country
  6. 10.2.1 South America Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antiangiogenic Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Antiangiogenic Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antiangiogenic Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Antiangiogenic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antiangiogenic Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antiangiogenic Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antiangiogenic Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Antiangiogenic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antiangiogenic Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antiangiogenic Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antiangiogenic Drugs Value Chain Analysis
  2. 12.1.1 Antiangiogenic Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antiangiogenic Drugs Production Mode & Process
  7. 12.2 Antiangiogenic Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antiangiogenic Drugs Distributors
  10. 12.2.3 Antiangiogenic Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst